Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ImClone, Sanofi-Aventis Settle Erbitux Patent Dispute

This article was originally published in The Pink Sheet Daily

Executive Summary

Each company will pay Israel’s Yeda $60 million, but ImClone also gains license for a patent critical to the production of cetuximab.

You may also be interested in...



ImClone Tussles With Another Partner, Merck KGaA

Merck KGaA seeks more than $18 million in damages, alleging ImClone licensed rights to Erbitux patents it did not own.

ImClone Tussles With Another Partner, Merck KGaA

Merck KGaA seeks more than $18 million in damages, alleging ImClone licensed rights to Erbitux patents it did not own.

North American Erbitux Sales Up 17 Percent In First Quarter

Positive clinical trial data, increased promotional efforts with partner Bristol-Myers Squibb drive gains, ImClone reports.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS065604

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel